Advertisement

Synageva BioPharma Corp. has landed a $25 million private equity funding to support development of the Lexington biotech’s enzyme replacement therapy, SBC-102.

The $25 million brings the company’s funding up to $70 million in the last two and a half years.

SOURCE

Advertisement
Advertisement